193
Participants
Start Date
March 22, 2018
Primary Completion Date
March 24, 2020
Study Completion Date
October 30, 2020
Palovarotene 2.5 mg
Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
Palovarotene 5.0 mg
Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
Placebo
Subjects received placebo, once daily, for up to 24 months.
Westmead Children's Hospital, Westmead
UZ Antwerpen, Edegem
The Children's Hospital of Philadelphia (CHOP), Philadelphia
Children's National Medical Center, Washington D.C.
Johns Hopkins University, Baltimore
Hospital Universitario La Paz, Madrid
Hôpital des Enfants, CHU de Toulouse, Toulouse
Bezmialem Vakif University Medical Faculty Hospital, Istanbul
Istituti Ortopedici Rizzoli, Bologna
Mayo Clinic - PPDS, Rochester
Shriners Hospital for Children - Chicago, Chicago
Hôpital universitaire Necker - Enfants Malades, Paris
Memorial Hermann Hospital, Houston
Children's Orthopaedic Center, Los Angeles
University of California-San Francisco, San Francisco
Shriners Hospital for Children - Sacramento, Sacramento
Shriners Hospitals for Children - Portland, Portland
The Paley Institute, West Palm Beach
Nagoya University Hospital, Nagoya
Boston Children's Hospital, Boston
Shriners Hospital for Children - Philadelphia, Philadelphia
Hospital for Sick Children, Toronto
Centre Hospitalier Universitaire Sainte-Justine, Montreal
Shriners Hospital for Children - Canada, Montreal
Osaka University Hospital, Suita
OLVG locatie Oost, Amsterdam
Hospital Pediátrico de Coimbra, Coimbra
Ege University Medical Faculty Hospital, Bornova
Evelina London Children's Hospital, London
Royal Manchester Childrens Hospital, Manchester
Royal National Orthopaedic Hospital, Stanmore
Lead Sponsor
Clementia Pharmaceuticals Inc.
INDUSTRY